ANT, INTU, AMD, INSM, GME: 5 Trending Stocks Today - Anthropic (NASDAQ:ANT)
U.S. stocks saw a broad decline on Thursday, marking the S&P 500's sixth consecutive drop. Despite the market downturn, several individual stocks including Anthropic PBC, Intuit Inc., Advanced Micro Devices Inc., Insmed Inc., and GameStop Corp. captured significant investor attention due to their IPO performance, earnings reports, regulatory concerns, acquisition rumors, and the reappearance of "Roaring Kitty."
Sanofi Weighs Takeover of Insmed; INSM Stock Surges 21% in Biggest Day Since August
Insmed Inc. (INSM) shares surged 21% after a report indicated Sanofi SA (SNY) is exploring a possible acquisition of the rare-disease drugmaker. Sanofi, under new CEO Belén Garijo, is looking for late-stage and commercial assets in immunology, rare diseases, and vaccines to bolster growth ahead of its Dupixent patent cliff. This potential deal, which could value Insmed at around $31 billion, would be one of the largest biopharmaceutical acquisitions in recent years.
Sanofi weighs takeover of US drugmaker Insmed, Bloomberg News reports
French drugmaker Sanofi is reportedly considering an acquisition of US drugmaker Insmed, according to Bloomberg News. Following the report, Insmed's shares rose 14%, giving it a market valuation of $26.28 billion. Sanofi has declined to comment on the market rumors, and Insmed has not yet responded to requests for comment.
Insmed jumps on report of Sanofi takeover interest
Insmed's stock surged 15% following a Bloomberg report that Sanofi is considering acquiring the drugmaker. Sanofi is reportedly consulting advisors regarding a potential deal for Insmed, which has a market cap of $26.3 billion. While deliberations are ongoing, there is no guarantee a transaction will occur, and other bidders could emerge.
Insmed shares jump 18% as Sanofi weighs potential takeover
Insmed shares surged 18% following reports that French pharmaceutical giant Sanofi is considering acquiring the US biotechnology company. Sanofi is reportedly speaking with advisers as it evaluates a potential deal, which could give it access to Insmed's treatments for respiratory and inflammatory diseases. While discussions are ongoing and a deal is not guaranteed, the news has drawn significant investor attention.
Insmed shares jump more than 18% on report Sanofi is weighing acquisition
Insmed shares surged over 18% after Bloomberg reported that Sanofi is considering acquiring the U.S. drugmaker. Sanofi is reportedly consulting advisors regarding a potential transaction, which could be one of the largest biopharmaceutical acquisitions in recent years. While discussions are ongoing, there is no guarantee a deal will be reached, and other bidders may emerge.
Should Raised Guidance Require Action From Insmed (INSM) Investors?
Insmed (INSM) reported strong Q3 2026 revenue of US$524.4 million and raised its full-year guidance for BRINSUPRI and ARIKAYCE, projecting a path to cash flow positivity. The company anticipates BRINSUPRI could achieve at least US$7 billion in peak sales. Investors are watching for BRINSUPRI's adoption, a January 2027 FDA decision for ARIKAYCE, and progress in its Duchenne gene therapy and idiopathic pulmonary fibrosis programs.
Insmed Sees BRINSUPRI Reaching $7 Billion in Peak Sales, Expects Cash-Flow Positive Year Ahead
Insmed anticipates its bronchiectasis drug BRINSUPRI to achieve $1.35 billion to $1.4 billion in sales in its first full year and eventually reach $7 billion in peak sales. The company plans a direct-to-consumer advertising campaign for BRINSUPRI and is exploring additional markets, including patients with COPD or asthma. Insmed also expects to become cash-flow positive next year while continuing to invest in its pipeline, including TPIP, ARIKAYCE, and a gene therapy program.
INSM: BRINSUPRI’s launch and pipeline underpin a multi-year growth runway
Insmed's BRINSUPRI launch in 2026 is projected to generate $1.35B-$1.4B, with significant future growth potential due to low market penetration and strong persistence. Key catalysts for 2027 include direct-to-consumer marketing, expansion into Japan, and additional ARIKAYCE launches, with the company anticipating cash-flow positivity. This outlook is based on the Insmed Incorporated Jefferies Global Healthcare Conference Audio Transcript from November 16, 2026.
Is Insmed (INSM) Still Undervalued Following Its Jefferies Conference Appearance?
Insmed (INSM) is presenting at the Jefferies Global Healthcare Conference, prompting a re-evaluation of its stock. Despite recent share price volatility with a 25.85% gain over the last month, the year-to-date return is still down 31.59%. Analysts at Simply Wall St believe Insmed is 38% undervalued with a fair value of $196.14, although its P/S ratio of 17.5x is higher than industry averages.
Is Insmed Stock Paying You Enough For The Swings?
Insmed (INSM) stock has shown high volatility with significant price swings, but its returns over the past five years have not adequately compensated investors for the extra risk compared to the S&P 500. The company, an unprofitable drugmaker, is in transition, with most of its revenue coming from BRINSUPRI and hopes for future profitability and new drug approvals. While Insmed's stock movements have largely been independent of the broader market, it adds specific risk related to new drug development rather than diversifying a portfolio.
Here’s How Much You Would Have Made Owning Insmed Stock In The Last 5 Years
Insmed (NASDAQ: INSM) has significantly outperformed the market over the past five years, generating an average annual return of 31.4%. An initial investment of $1,000 in INSM stock five years ago would now be worth $3,750.47, highlighting the substantial impact of compounded returns.
Insmed (INSM) Raises 2026 Guidance Following Earnings, Is It Still Below Fair Value?
Insmed (INSM) recently updated its 2026 guidance, reporting a narrower net loss and increased revenue guidance for key therapies BRINSUPRI and ARIKAYCE after its third-quarter update. Despite a 35.41% year-to-date share price fall, long-term investors are well ahead due to a nearly 4x three-year total shareholder return, and the stock is considered undervalued by analysts with a fair value estimate of $196.14 per share, significantly above its current trading price of $114.41. However, potential risks include BRINSUPRI's uptake in non-US markets and ARIKAYCE's label expansion outcomes, while its P/S ratio of 16.5x is higher than industry averages.
Insmed Incorporated (INSM) Seasonal Returns Chart - Yahoo Finance
The article provides a seasonal returns chart for Insmed Incorporated (INSM), displaying the average monthly price return for the period between 2016 and 2026. It shows the company's stock performance and related market data on Yahoo Finance, including current price, daily change, and after-hours trading information.
Insmed to Present at November and December 2026 Investor Conferences
Insmed Incorporated announced that its management will present at two upcoming investor conferences: the Jefferies Global Healthcare Conference on November 16, 2026, and the Evercore 9th Annual Healthcare Conference on December 1, 2026. Both events will be webcast live and accessible via the company's investor relations website. Insmed is a global biopharmaceutical company focused on delivering therapies for serious diseases, with a diverse portfolio and pipeline in respiratory, immunology & inflammation, and neuro & other rare therapeutic areas.
Two Insmed talks will stream live from London and Florida
Insmed (Nasdaq: INSM) announced that its management will present at two upcoming investor conferences: the Jefferies Global Healthcare Conference in London on November 16, 2026, and the Evercore 9th Annual Healthcare Conference in Coral Gables, Florida, on December 1, 2026. Live webcasts of both presentations will be accessible through Insmed's investor relations website, with archives available for 30 days. The presentations will detail the company's progress as a biopharmaceutical firm focused on delivering therapies for serious diseases.
H.C. Wainwright initiates Insmed stock coverage with buy rating By Investing.com
H.C. Wainwright initiated coverage on Insmed Incorporated (NASDAQ:INSM) with a buy rating and a price target of $220.00, citing the company's transition into a multi-asset respiratory commercial business with combined peak sales guidance exceeding $14 billion. Despite the stock appearing slightly overvalued at its Fair Value of $100.42 according to InvestingPro data, analyst consensus remains bullish. The firm expects Insmed to achieve cash-flow positivity in 2027 without needing new capital, even after the company reported strong Q3 2026 revenue but adjusted losses per share.
Insmed to present at major healthcare conferences in London and Florida in November-December 2026
Insmed Incorporated announced it will present at two major healthcare conferences: the Jefferies Global Healthcare Conference in London on November 16, 2026, and the Evercore 9th Annual Healthcare Conference in Florida on December 1, 2026. These presentations will be webcast live and archived on Insmed's website, offering an opportunity to update investors on its progress in developing therapies for serious diseases. The article also provides a brief market snapshot for the Health sector.
Nine option positions accompany a controller’s 9,921-share holding in Insmed (INSM).
Insmed's Corporate Controller, Patrick Kevin Kane, has reported direct ownership of 9,921 common stock shares, which include restricted stock units (RSUs). These RSUs have various vesting schedules, and he also holds nine direct stock-option positions with exercise prices ranging from $17.07 to $177.12 and expiration dates extending from January 2032 to January 2036. This information was disclosed in an SEC Form 3 filing.
Tax withholding prompted a former officer's $1.12M share sale at Insmed (INSM).
Sara Bonstein, a former officer of Insmed (INSM), reported the sale of 10,261 common shares valued at approximately $1.12 million through Merrill Lynch on November 3, 2026. The sale was conducted to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. This transaction was disclosed in an SEC Form 144 filing.
Guggenheim cuts Insmed stock price target on model changes to $201
Guggenheim has reduced its price target for Insmed Inc. (NASDAQ:INSM) to $201 from $205, while maintaining a Buy rating, due to model adjustments after the company's strong third-quarter 2026 results. Insmed's Brinsupri sales exceeded expectations, and the company continues to project over 20% sales compound annual growth rate for the next decade, though InvestingPro analysis suggests the stock is currently trading above its Fair Value. Other firms like Goldman Sachs and Stifel also reiterated Buy ratings with slightly different price targets following Insmed's mixed Q3 earnings.
Weekly Recap: Q3 revenue growth and positive ENCORE results
Insmed Incorporated (NASDAQ:INSM) reported a significant 268% Q3 revenue growth and narrowed net losses, leading to raised 2026 guidance. The company also announced positive ENCORE results, received FDA Priority Review for ARIKAYCE, and saw strong global sales for BRINSUPRI, alongside advancing its Phase 3 TPIP trials and appointing two new directors to its board.
Is Insmed (INSM) Cheap After Strong Revenue And Higher 2026 Guidance?
Insmed (INSM) has seen a positive shift in sentiment following strong third-quarter revenue, driven by BRINSUPRI and ARIKAYCE, and increased full-year 2026 guidance. Despite recent share price gains, the stock has declined significantly year-to-date, though long-term holders have seen substantial returns. The company is currently considered 43% undervalued, with a fair value of $196.14, based on its respiratory franchise potential, but faces risks such as European BRINSUPRI rollout hurdles.
Goldman Sachs reiterates Insmed stock rating on Brinsupri beat
Goldman Sachs reiterated a Buy rating and a $194.00 price target for Insmed (NASDAQ:INSM) after the company's Brinsupri product exceeded revenue estimates, reporting $400.1 million. The firm also increased its 2027 forecast for Brinsupri to $2.7 billion and expects Insmed to achieve cash flow positivity by 2027. Insmed's stock surged by 19.5% to $111.59, and the company raised its fiscal year 2026 Brinsupri guidance.
INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance
Insmed (INSM) reported a wider-than-expected loss of 46 cents per share in Q3 2026, but its stock surged 15% due to a significant 268% year-over-year revenue increase to $524.4 million, beating consensus estimates. The strong performance was driven by robust sales of Brinsupri and Arikayce, leading the company to raise its full-year 2026 revenue guidance for both products. Insmed also provided positive updates on its pipeline, including regulatory approvals and advancements in late-stage clinical trials.
Why Did Insmed Stock Jump?
Insmed (INSM) shares rose 15.1% on October 29, 2026, following the release of its third-quarter 2026 results. The company beat revenue estimates, reporting $524.4 million, primarily driven by its newer drug BRINSUPRI, and raised its full-year 2026 revenue guidance for both BRINSUPRI and ARIKAYCE. Despite a wider-than-expected loss per share, the strong sales performance and positive outlook contributed to the stock's significant jump, outperforming the broader healthcare sector.
Insmed jumps after strong Q3 revenue growth and higher 2026 product guidance
Insmed (INSM) shares rose 16.6% following a robust third-quarter report, driven by strong BRINSUPRI sales and increased full-year revenue guidance for both BRINSUPRI and ARIKAYCE. The company also reported a significantly narrower net loss, exceeding Wall Street expectations. Insiders have primarily sold shares in the past six months, while institutional investors show mixed activity with some large additions and removals.
Insmed Incorporated 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:INSM)
Insmed Incorporated published its slide deck in conjunction with its Q3 2026 earnings call. This article, provided by SA Transcripts, highlights the availability of these materials for investors. Seeking Alpha's transcripts team is responsible for publishing numerous quarterly earnings calls to expand their coverage.
Insmed Incorporated (INSM) Q3 Revenue $524.4M; Raises 2026 Guidance
Insmed Incorporated (INSM) reported strong Q3 2026 revenue of $524.4M, driven by BRINSUPRI at $400.1M and ARIKAYCE at $124.4M. The company subsequently raised its 2026 revenue guidance for both products, signaling robust growth momentum, particularly for BRINSUPRI after its rapid launch and expansion into Japan. This update confirms strong performance and sets a positive outlook for the company's financial year.
Insmed 3Q 2026: Revenue $524.4M, Net loss $100.3M, EPS $(0.46) — 10-Q Summary
Insmed reported strong third-quarter 2026 financial results, with revenue soaring to $524.4M, a 268% increase year-over-year, primarily due to BRINSUPRI sales. The company significantly reduced its net loss to $100.3M, or $0.46 per diluted share, compared to a $370M net loss in the prior-year quarter. Key business highlights include the launch of BRINSUPRI in Japan and progress in other clinical programs for its drug pipeline.
Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update
Insmed Incorporated announced strong financial results for the third quarter of 2026, with total company revenues reaching $524.4 million. This was driven by significant growth in BRINSUPRI® revenues, which increased by 29% over the previous quarter, and continued growth in ARIKAYCE® revenues, up 9% year-over-year. The company also raised its full-year 2026 revenue guidance for both products and highlighted regulatory approvals and pipeline advancements, including the launch of BRINSUPRI in Japan and the FDA's acceptance of an sNDA for ARIKAYCE.
Insmed set to report earnings as Japan launch tests growth story
Insmed is preparing to release its third-quarter earnings, with analysts forecasting a loss of 39 cents per share on revenue of $497.1 million, despite strong "Strong Buy" ratings and significant upside potential. Investors will closely watch the commercial performance of Brinsupri following its recent launch in Japan, along with progress on the treprostinil palmitil inhalation powder (TPIP) program, as the company aims for cash-flow positivity by 2027 amid cautious market sentiment regarding its path to profitability.
Insmed reaffirms FY26 revenue guidance for Brinsupri and Arikayce
Insmed Inc. has reaffirmed its full-year 2026 revenue guidance for its key products, BRINSUPRI and ARIKAYCE, citing continued operational excellence. The company expects BRINSUPRI to generate $1.25 billion to $1.40 billion, while ARIKAYCE is projected to bring in $450 million to $470 million for FY26. This guidance highlights BRINSUPRI as the primary revenue driver, significantly outpacing ARIKAYCE in projected sales.
How Japan Launch Of BRINSUPRI At Insmed (INSM) Has Changed Its Investment Story
Insmed has launched BRINSUPRI Tablets in Japan, the first approved therapy for non-cystic fibrosis bronchiectasis in a major pharmaceutical market. This introduces a new revenue stream and diversifies the company's investment narrative, which previously relied heavily on US execution for brensocatib. The launch, along with recent board appointments, signals an operational focus on commercialization and global market access.
Insmed Incorporated Estimates – NASDAQ:INSM
This article provides an overview of Insmed Incorporated (NASDAQ: INSM) financial actuals and analyst estimates available on TradingView. It highlights various financial data points including income statement, balance sheet, cash flow statement, and valuation metrics, allowing users to compare actual results with average, high, and low estimates. The content emphasizes that this information is not investment advice and encourages users to conduct their own research.
Insmed Incorporated Estimates – BMV:INSM
This page provides financial estimates for Insmed Incorporated (INSM) on the Mexican Stock Exchange (BMV). It offers access to reported financial data and analyst estimates across various statements and metrics, allowing users to compare actual results with average, high, and low estimates and visualize trends over time. The available data covers income statements, balance sheets, cash flow, and can be viewed annually or quarterly.
Insmed unveils BRINSUPRI in Japan offering first approved treatment for bronchiectasis
Insmed Incorporated has launched BRINSUPRI (brensocatib hydrate) in Japan, marking the country's first approved and commercially available treatment for non-cystic fibrosis bronchiectasis (NCFB). This once-daily oral therapy is available for adults and pediatric patients aged 12 and older, targeting the underlying inflammatory process of the disease. The approval by Japan’s Ministry of Health, Labour and Welfare in August 2026 was based on positive results from the Phase 3 ASPEN clinical trial.
Insmed Needs Brinsupri To Prove Its Organic Ramp After A 25% Post-Raise Slide
Insmed's shares have fallen significantly despite confident guidance for its new bronchiectasis drug, Brinsupri. Investors are now looking for proof of organic growth, particularly through patient refills and increased prescriber depth, in the upcoming Q3 earnings report. The key challenge is to demonstrate sustained growth after the initial launch backlog has been exhausted, validating management's optimistic outlook.
Form 4 Insmed Inc: Paul Hudson (Director) For: 19 October By Investing.com
This article reports on a Form 4 filing for Insmed Inc., detailing director Paul Hudson's activities for October 19th. Form 4 filings are regulatory documents that disclose changes in the ownership of company stock by insiders. The article indicates that additional details about this specific transaction would be available within the full Form 4 document.
A no-cost grant gives Insmed (INSM) director Paul Hudson 6,139 stock units.
Insmed director Paul Hudson was granted 6,139 restricted stock units (RSUs) on October 19, 2026, under the company's Amended and Restated 2019 Incentive Plan. These RSUs were granted for no consideration and will vest in equal annual portions over three years, contingent on Hudson remaining a director. This transaction was reported in an SEC Form 4 filing.
Form 4 Insmed Inc: Paul Hudson (Director) For: 19 October By Investing.com
This article reports a Form 4 filing for Insmed Inc., indicating that Paul Hudson, a director, made a transaction on October 19th. The piece is a brief notification of this insider trading activity.
Utpal Koppikar Appointed to Insmed Board, Reports No Ownership of Company Securities
Utpal Koppikar has been appointed as a director of Insmed Incorporated, a NASDAQ-listed biopharmaceutical company. This appointment was officially reported to the SEC on October 20, 2026, following a triggering event on October 19, 2026. The filing explicitly states that Mr. Koppikar does not beneficially own any of Insmed's securities.
Form 3 INSMED Inc For: Oct 19 Filed by: Hudson Paul
This article reports on a Form 3 filing with the SEC for INSMED Inc., indicating the initial statement of beneficial ownership of securities. The filing is for Paul Hudson, who is listed as a Director, and pertains to an event requiring the statement on October 19, 2026. The document details the required information for an initial statement of beneficial ownership for non-derivative and derivative securities.
A no-cost grant gives Insmed (INSM) director Utpal Koppikar 6,139 stock units.
Insmed (INSM) director Utpal Koppikar was granted 6,139 restricted stock units (RSUs) on October 19, 2026, without consideration. These RSUs, each representing a contingent right to one common share, will vest in equal parts over the first three one-year anniversaries of the grant date. Vesting is conditional upon Koppikar's continued service as a director for Insmed.
Insmed Appoints Former Sanofi CEO Paul Hudson and Utpal Koppikar to Board
Insmed Incorporated (Nasdaq: INSM) has appointed former Sanofi CEO Paul Hudson and Verily Health CFO Utpal Koppikar as independent directors, effective October 20. These appointments aim to strengthen Insmed's board with extensive commercial and financial expertise, supporting the biopharmaceutical company's global expansion and diversified drug development pipeline. The new directors bring significant experience in multinational pharmaceutical operations, commercial strategy, corporate finance, and organizational growth, which will be invaluable as Insmed manages its expanding portfolio of approved and investigational medicines.
Form 8K Insmed Inc For: 20 October By Investing.com
This article reports that Insmed Inc. filed a Form 8K on October 20th. The filing is an important regulatory disclosure for publicly traded companies. No specific details about the content of the 8K filing are provided in this brief announcement.
Insmed adds two independent directors with biopharma backgrounds
Insmed Incorporated has appointed Paul Hudson and Utpal Koppikar as independent members of its board of directors. Paul Hudson previously served as CEO of Sanofi S.A. and Novartis Pharmaceuticals, bringing extensive commercial and strategic acumen. Utpal Koppikar, the current CFO of Verily Health Inc., has a strong financial background from companies like Gilead Sciences and Amgen.
Insmed appoints Paul Hudson and Utpal Koppikar to its Board
Insmed has announced the appointment of Paul Hudson and Utpal Koppikar to its Board of Directors, effective October 19, 2026. Paul Hudson will join the Compensation Committee, bringing experience as a former CEO of Sanofi and Novartis Pharmaceuticals. Utpal Koppikar will join the Audit Committee, leveraging his background as the current CFO of Verily Health and former EVP & CFO at Atara Biotherapeutics.
Insmed Appoints Two New Directors to Its Board
Insmed Incorporated announced the appointment of Paul Hudson and Utpal Koppikar as independent members of its Board of Directors, effective immediately. These additions bring extensive experience in global biopharma leadership, commercial strategy, and financial management to Insmed's Board. The company aims to leverage their expertise to advance its portfolio and continue its mission to transform the lives of patients with serious and rare diseases.
Oral Lung-Disease Tablets: Insmed Brings BRINSUPRI to Japan for NCFB
Insmed has launched BRINSUPRI Tablets 25 mg in Japan, providing the first and only approved oral once-daily treatment option for adults and pediatric patients aged 12 and older with non-cystic fibrosis bronchiectasis (NCFB). This brensocatib hydrate tablet aims to target the underlying inflammatory process of the disease, moving care beyond just symptom management. The availability of BRINSUPRI in Japan represents a significant shift towards disease-modifying treatments for chronic lung conditions and highlights opportunities for global biopharma firms in regulated regional markets.